Acute & MSK · Full case

Chronic Primary Pain

NICE NG193Biopsychosocial
C
Chronic Pain · Clinical Reasoning Framework v2
GP & SCA · NICE NG193 (2021) · CKS Chronic Pain 2022 · Biopsychosocial model
43%UK adults with chronic pain; 14% significantly disabled — most common reason for GP consultation
3 monthsClinical threshold for chronic pain; NICE NG193 applies to pain persisting beyond normal tissue healing time
NICE NG1932021 landmark guideline: do NOT offer opioids, gabapentinoids, or paracetamol for chronic primary pain — exercise and ACT/CBT first
ExerciseMost evidence-based intervention for chronic primary pain — any modality; supervised or self-directed; improves pain, function, and mood
ACT / CBTPsychological first-line (alongside exercise) per NICE NG193 — Acceptance and Commitment Therapy or CBT; targets catastrophising and avoidance
OIHOpioid-Induced Hyperalgesia — chronic opioids paradoxically increase pain sensitivity; counter-intuitive; key reason opioids fail and need tapering
CatastrophisingPain catastrophising (rumination, magnification, helplessness) is the single strongest predictor of disability — not pain intensity; target of ACT/CBT
BiopsychosocialChronic pain is not just nociception — psychological (catastrophising, depression, fear-avoidance) and social factors amplify and maintain pain
📋 Clinical Stem — Chronic Primary Pain
A 58-year-old retired teacher requesting stronger pain medication for 4-year chronic low back pain with normal recent MRI
Margaret Davies, 58, retired teacher, attends requesting "something stronger" for her back pain. She has had low back pain since a lumbar disc prolapse 4 years ago, which resolved radiologically — a recent MRI showed disc dehydration only, no significant nerve root compression. Despite this, she rates her pain 7–8/10 most days. She has been on tramadol 100mg BD and duloxetine 60mg OD for 2 years with incomplete relief. She has significantly reduced her activities, stopped walking, and reports that her mood has been low and her sleep poor. She feels "dismissed" by previous GPs who told her the MRI was normal and she should be fine. She wants to be referred for "something stronger — maybe morphine." She has a PHQ-9 of 12 (mild-moderate depression).
This stem tests five clinical skills: applying NICE NG193 (2021) — which explicitly recommends against opioids, gabapentinoids, and routine paracetamol for chronic primary pain; explaining the biopsychosocial model of pain in accessible language without invalidating the patient's experience; addressing the "my MRI is normal but I'm in real pain" narrative; discussing opioid-induced hyperalgesia honestly; and offering exercise and ACT/CBT as evidence-based alternatives that work better than escalating medication.
Scenario A — Fibromyalgia 45-year-old woman, widespread musculoskeletal pain, fatigue, cognitive difficulties ("fibro fog"), poor sleep, multiple tender points. Fibromyalgia: central sensitisation syndrome; NICE recommends duloxetine (licensed for fibromyalgia), low-dose amitriptyline (evidence for sleep and pain), aerobic exercise (strongest single intervention), CBT. Opioids not recommended — cause OIH. The FIQ-R (Fibromyalgia Impact Questionnaire) for severity.
Scenario B — Neuropathic Pain (Post-Herpetic Neuralgia) 72-year-old man, burning, shooting pain in the left chest wall following shingles 8 months ago. Neuropathic pain: gabapentinoids (pregabalin/gabapentin) are licensed for neuropathic pain — note that NICE NG193 recommends AGAINST them for chronic primary pain but they DO have evidence for neuropathic pain. Duloxetine, amitriptyline, capsaicin patch (specialist) also evidence-based. PHQ-9 essential — depression highly comorbid with neuropathic pain.
Scenario C — Opioid De-Prescribing 52-year-old man on morphine 60mg BD (oral) for 3 years for chronic low back pain. MRI: mild degenerative changes only. He has noticed the morphine "isn't working like it used to" and has been increasing the dose himself. NICE NG193: do not start opioids for chronic primary pain; if already prescribed, discuss tapering. Opioid-induced hyperalgesia: opioids increase central sensitisation over time. Tapering plan: reduce by 10% every 2–4 weeks; buprenorphine patch as bridge; pain psychology essential during taper.
Scenario D — Pain Catastrophising and Fear-Avoidance 40-year-old woman, 2 years after a minor RTA, increasing disability despite normal investigations. Pain catastrophising: "I am going to be in pain forever; the pain means my back is being damaged every time I move; I cannot do anything." Fear-avoidance model: fear of pain → avoidance → deconditioning → more pain. ACT target: acceptance of pain without avoidance; committed action toward valued living despite pain. Graded return to activity is the primary intervention.
Scenario E — Persistent Pain After Cancer Treatment 55-year-old woman, 2 years post-breast cancer treatment, chemotherapy-induced peripheral neuropathy (CIPN). Persistent pain after cancer treatment is a distinct entity — different pathophysiology from primary chronic pain; specialist oncology pain service; duloxetine has evidence specifically for CIPN. PHQ-9 essential — depression comorbid with cancer pain. NICE NG193 chronic primary pain recommendations do NOT fully apply to cancer-related pain.
Key variables to adapt for Pain type (primary vs secondary to identifiable pathology), subtype (musculoskeletal, neuropathic, fibromyalgia, visceral), current medications (opioids to taper; gabapentinoids to review), comorbidities (depression in 60%; anxiety; sleep disorder), catastrophising level (PCS score), activity level (deconditioning), social factors (work absence, benefits, litigation), and cultural context around pain expression and stoicism.
Steps:
1
Step 1
History Taking — Open Question · Biopsychosocial Assessment · Catastrophising · Red Flags · ICE
collapse
The chronic pain history has one structural requirement: assess the whole person, not just the pain. NICE NG193 (2021) is explicit that chronic pain is maintained by biopsychosocial factors — biological (nociception), psychological (catastrophising, depression, fear-avoidance, self-efficacy), and social (work, relationships, isolation, meaning). A history that focuses only on the pain location and intensity misses the primary treatment targets. The GP who asks "where is the pain and how bad is it?" without asking "how is the pain affecting your life?" has a pharmaceutical frame, not a chronic pain frame.
🎓 SCA framing — validate first, then broaden
"Before we go through everything, I want to say something important: I believe your pain is real. When an MRI is normal and a person is still in significant pain every day, that does not mean the pain is imagined — it means the type of pain we are dealing with has a different mechanism than what shows up on a scan. I want to understand the pain properly, and I want to understand how it is affecting your whole life, not just where it hurts."
Margaret has been told her MRI is normal and she "should be fine" — the most invalidating experience in chronic pain medicine. Validating the pain before anything else re-establishes trust, without which the management plan will not be heard.
1A — Open question then comprehensive pain history
QuestionWhy it mattersChanges what?
🟢 OPEN QUESTION"Tell me about the pain — not just where it is and how bad it is, but what it has done to your life. What can you no longer do? What is a typical day like for you now compared with before?" The open narrative reveals the biopsychosocial impact of chronic pain across all domains simultaneously. A patient whose day involves waking in pain, avoiding the activities she used to love, watching her social circle shrink, and watching daytime television because movement makes it worse has described: physical deconditioning (avoidance of activity), psychological withdrawal (depression), and social isolation — all of which are maintaining the pain and all of which are treatment targets. None of this emerges from "where does it hurt and how bad is it?"In SCA: a candidate who asks only about pain location, intensity, and medication has a pharmaceutical frame. The chronic pain candidate who achieves a high score is one who identifies functional impairment, catastrophising, fear-avoidance, depression, and what the patient has lost — before discussing any treatment. Biopsychosocial profile; function; catastrophisingLoss of identity; meaning; social isolation
Pain characteristics and type"Describe the pain — is it constant or comes and goes? Burning, shooting, aching, stabbing? Is it in one place or widespread? Does movement make it worse or better?"Pain type determines pharmacological approach: nociceptive (aching, throbbing, worsened by loading) vs neuropathic (burning, shooting, electric-shock, dysaesthesia) vs nociplastic/central sensitisation (widespread, unpredictable, hypersensitivity — allodynia: pain from light touch; hyperalgesia: magnified pain from noxious stimulus). Central sensitisation is the dominant mechanism in chronic primary pain and fibromyalgia — it does not respond well to tissue-directed treatments (surgery, NSAIDs, opioids).Allodynia (pain from normally non-painful stimuli, e.g. light clothing touch causing burning) is pathognomonic of central sensitisation and is one of the most important history findings in chronic pain — it immediately indicates that peripheral tissue-directed treatment will fail and that central sensitisation-targeting approaches are needed.Neuropathic → duloxetine/amitriptyline/gabapentinoid. Nociplastic/central → exercise + ACTAllodynia: gabapentinoid if neuropathic; ACT if central sensitisation
Functional impairment"What can you no longer do because of the pain? Walks, social events, driving, cooking, working? What are you doing less of than you used to?"Functional impairment in chronic pain has two components: direct limitation from pain (cannot walk far) and fear-avoidance (avoids activity because of catastrophic fear of causing damage). The functional impairment is both a measure of disease severity and the primary treatment outcome — NICE NG193 measures treatment success by improvement in function and quality of life, not pain reduction. A patient who reduces pain from 8/10 to 6/10 but increases walking from 50m to 2km has improved meaningfully.The Chronic Pain Grade (von Korff) assesses both pain intensity and disability — it is the most commonly used outcome measure in chronic pain research. In primary care, asking "what has the pain stopped you doing?" and "what activities have you given up?" provides the same functional information.Deconditioning: graded exercise programme; physiotherapy referralFear-avoidance: ACT/CBT target; graded exposure to feared activities
Pain catastrophising screen"When you are in pain, what goes through your mind? Do you find yourself thinking it will never get better, or that something terrible is being damaged inside? Do you feel helpless about it?"Pain catastrophising is a pattern of excessive negative cognitive responses to pain: rumination ("I can't stop thinking about how much it hurts"), magnification ("the pain means there must be serious damage"), and helplessness ("there is nothing I can do about this"). The Pain Catastrophising Scale (PCS) can be used in primary care. Catastrophising is the single strongest predictor of pain-related disability — stronger than pain intensity itself. It is the primary target of ACT and pain-focused CBT.The patient who says "when my back hurts I think I am destroying it and it will never get better and nothing will help" has a catastrophising thought pattern that will maintain their disability regardless of whether the pain itself improves. ACT specifically targets acceptance rather than catastrophic interpretation of pain.Catastrophising: ACT/CBT first-line; self-management programmeCatastrophising → NICE NG193 psychological pathway
Mood, sleep, and wellbeing"How has your mood been through all of this? Are you sleeping? Has the pain affected your sense of who you are?"Depression and anxiety are present in 40–60% of chronic pain patients — they are not separate conditions but are bidirectionally linked. Chronic pain causes depression (through functional loss, social isolation, identity loss); depression amplifies pain (through central sensitisation amplification, reduced inhibitory pain pathways). The PHQ-9 and GAD-7 are mandatory at every chronic pain consultation. SSRI/SNRI treatment of depression in chronic pain patients significantly improves pain outcomes — not just mood. Treating only the pain while ignoring the depression produces inferior outcomes.Sleep disturbance and pain form a vicious cycle: pain disrupts sleep; poor sleep reduces the pain inhibitory system (descending noradrenergic pathways); reduced inhibition means more pain; more pain disrupts sleep further. Addressing the sleep disorder in chronic pain is not a secondary consideration — it is a pain-modulating intervention.PHQ-9 mandatory; duloxetine for depression + pain; sleep programmeDepression amplifies chronic pain; must be treated concurrently
Current medication and previous treatments"What have you tried for the pain — what has helped, what hasn't, and what are you currently taking? How long have you been on the tramadol?"Current opioid use (tramadol) must be assessed for: dose and duration (long-term opioid use in chronic primary pain is associated with worse outcomes); opioid-induced hyperalgesia (increasing dose requirement with no improvement in function); psychological dependence; side effects (constipation, cognitive impairment, falls risk). NICE NG193: if opioids are already prescribed for chronic primary pain, clinicians should discuss tapering — not escalation. Margaret's tramadol has been running for 2 years with incomplete relief — this is a de-prescribing opportunity, not an escalation indication.Opioid-induced hyperalgesia (OIH): chronic opioid use paradoxically increases pain sensitivity by down-regulating descending inhibitory pain pathways and up-regulating NMDA receptor excitability. Patients experience this as escalating pain despite increasing doses. OIH should be explained to the patient as the reason their tramadol is "not working like it used to" — it is not that they need more, it is that the opioid is part of the problem.Tramadol: OIH assessment; de-prescribing discussion if chronic primary painEscalating opioid dose with no functional benefit: OIH likely
Social context and work history"What is your situation at work or occupation? Is the pain affecting your finances, your benefits, or any legal proceedings? How are your close relationships?"Social factors significantly influence chronic pain outcomes. Work absence: associated with worse prognosis; return to work (even modified duties) is a treatment goal. Benefits and litigation: medico-legal involvement prolongs recovery in pain conditions (not because of malingering but because adversarial systems reinforce pain behaviour and identity). Relationships: isolation worsens pain; family responses to pain (over-protective vs dismissive) both maintain pain behaviour. Social prescribing, activity programmes, and peer support are underused chronic pain interventions.The term "secondary gain" (continued pain behaviour being reinforced by benefits or legal compensation) is often used pejoratively and is rarely the primary driver of chronic pain presentation. However, the social context of chronic pain — including financial insecurity, relationship breakdown, and loss of occupational identity — is clinically important because it predicts outcomes and identifies social prescribing targets.Social isolation: social prescribing; community activitiesOccupational rehabilitation; return to work support
Red flag exclusion"Is there anything new about the pain — different quality, new location, worse at night, associated with weight loss or weakness?"Established chronic pain can have new red flag features superimposed. The patient with 4-year back pain who develops new night pain, weight loss, or lower limb weakness needs malignancy and cord compression excluded regardless of the chronic pain history. Red flags must be actively re-screened at every chronic pain consultation — not assumed to have been excluded by the initial assessment.Cauda equina syndrome can develop insidiously in patients with pre-existing back pain — new saddle anaesthesia, bilateral leg symptoms, or bladder/bowel dysfunction should prompt immediate MRI even if the patient's pain pattern is familiar.Red flag: saddle anaesthesia + bilateral weakness = cauda equina → 999New night pain + weight loss + known cancer = MRI urgent
1B — Red flags: do not attribute to established chronic pain
🚨

Red Flags — exclude new serious pathology in chronic pain patients

Red flagWhy importantAction
Saddle anaesthesia + bilateral leg weakness + bladder/bowel dysfunctionCauda equina syndrome — surgical emergency. Can develop insidiously in pre-existing lumbar back pain. Missing it leads to permanent neurological injury. Saddle anaesthesia (inner thighs, perineum) is the most specific feature.999 / Emergency MRI / immediate neurosurgery referral
New or significantly changed pain in known cancer patientBone metastases; spinal cord compression; malignant nerve infiltration. Pain change in a cancer patient requires imaging before any pain management adjustment.Urgent MRI / CT; oncology same day
New pain with fever + systemic features + focal neurological deficitSpinal epidural abscess or discitis — can mimic chronic back pain exacerbation. Associated fever and raised inflammatory markers distinguish it. Urgent MRI and infectious disease involvement.Urgent MRI spine; FBC/CRP/ESR; blood cultures; emergency admission if sepsis
Night pain waking from sleep + unexplained weight loss in a patient >50Vertebral metastases; multiple myeloma; primary bone tumour. Night pain that wakes from sleep is not mechanical — it is the most sensitive red flag for vertebral malignancy.Urgent MRI spine; bloods (ESR, LDH, protein electrophoresis, ALP); 2WW if malignancy suspected
Suicidal ideation in chronic painSuicide risk is significantly elevated in chronic pain (2–3× general population). Pain catastrophising + hopelessness about recovery is the primary driver. PHQ-9 item 9 must be screened at every chronic pain consultation.PHQ-9; direct suicidal ideation screen; same-day crisis if active ideation with plan
🛡️

Safeguarding Considerations in Chronic Pain

💊 Opioid Risk and Diversion
  • Chronic opioid prescribing creates risk of misuse, dependence, and diversion to others in the household (including children)
  • Assessment: is the patient taking opioids as prescribed? Any dose escalation? Any requests for early prescriptions?
  • Children in the household of a patient on high-dose opioids: potential accidental ingestion risk; medication storage discussion mandatory
  • Opioid prescribing should be reviewed at every consultation with documented clinical indication and functional benefit assessment
🏠 Domestic Abuse and Chronic Pain
  • Chronic pain (particularly widespread musculoskeletal and pelvic pain) has a strong association with domestic abuse and adverse childhood experiences
  • Screen using HARK (Humiliation, Afraid, Rape, Kick) questionnaire in unexplained or unusual chronic pain presentations
  • Domestic violence can present as chronic pain through: repeated physical injury; stress-related central sensitisation; medically unexplained symptoms from chronic trauma
  • Safety planning: MARAC if high-risk; IDVA; children's social care if children in household
🧒 Children in the Household
  • Parental chronic pain significantly impacts children: reduced parental engagement; financial hardship from work absence; modelling of pain behaviour (children of chronic pain patients have higher rates of chronic pain themselves)
  • PHQ-9 and parenting capacity assessment when parental chronic pain is severely functionally impairing
  • Social prescribing: family support; young carers assessment (if children are fulfilling carer roles for a chronically ill parent)
⚠️ Chronic Pain and Self-Harm Risk
  • Chronic pain doubles suicide risk; PHQ-9 at every consultation; direct suicidal ideation screen
  • Opioid stockpiling: patients with chronic pain on long-term opioids may accumulate doses; at-risk patients may be stockpiling for overdose
  • Safe storage and prescription quantities: monthly prescriptions for opioids in patients with any mood instability or suicidal ideation history
  • Hopelessness about pain recovery + depression is the highest-risk combination: same-day crisis assessment if active ideation
Safeguarding principle: Screen for domestic abuse in unexplained chronic pain. Opioid prescribing review: safe storage; diversion risk; children in household. Suicidal ideation: PHQ-9 at every chronic pain consultation. Parenting capacity if severely disabled parent with young children. Young carers assessment.
1C — PMH · FH · Drug history
🧬 PMH / FH
FactorWhy it mattersManagement impact
Depression / anxiety40–60% comorbidity with chronic pain. Bidirectional: pain causes depression; depression amplifies pain through central sensitisation. PHQ-9 at every consultation. Untreated depression is the most modifiable predictor of poor chronic pain outcome.SSRI/SNRI treats both (duloxetine most evidence for pain + depression). Antidepressant treatment significantly improves pain outcomes. Psychological therapy (ACT/CBT) for both simultaneously.
Previous trauma (ACEs, PTSD)Adverse childhood experiences strongly predict chronic pain in adulthood. Trauma sensitises the central nervous system to pain amplification. Central sensitisation syndrome (fibromyalgia, IBS, chronic headache, chronic pelvic pain) frequently follows trauma history.Trauma-informed approach. PTSD management alongside pain management. ACT particularly effective for trauma-related pain.
Chronic kidney disease / liver diseaseMost analgesics require dose adjustment in renal or hepatic impairment. NSAIDs: contraindicated in CKD. Tramadol: accumulates in CKD; lower doses. Gabapentinoids: renal dose adjustment essential. Opioids: accumulate in hepatic failure.eGFR at every chronic pain medication review. NSAID avoidance in CKD. Paracetamol (max 3g/day) preferred in CKD. Gabapentinoid dose adjustment per BNF.
Previous substance misuseHistory of alcohol or substance misuse significantly increases opioid dependence risk. NICE NG193: consider carefully before prescribing opioids in this group. Non-opioid pharmacological and non-pharmacological approaches should be prioritised.Opioid prescribing: avoid or use with extensive monitoring and support. Monthly prescriptions only. Consider buprenorphine (partial agonist; lower misuse potential) if opioid needed. CURAT addiction services if needed.
💊 Drug history — medication review
FactorWhy it mattersImpact
Long-term opioid useChronic opioids for chronic primary pain: associated with worse long-term outcomes; opioid-induced hyperalgesia; dependence; side effects (constipation, cognitive impairment, falls, hormonal). NICE NG193: discuss tapering in all patients on long-term opioids for chronic primary pain.Opioid tapering plan: 10% reduction every 2–4 weeks; buprenorphine as transition; pain psychology essential. Do NOT abruptly stop. Document functional benefit assessment.
Gabapentinoid use (pregabalin / gabapentin)NICE NG193: do NOT start gabapentinoids for chronic primary pain. For patients already on them: review regularly for benefit vs harm. Class C controlled drugs (since 2019); misuse potential. Significant side effects: dizziness, falls, cognitive impairment, respiratory depression with opioids.If prescribed for chronic primary pain without neuropathic features: discuss tapering. If neuropathic pain: may be appropriate. Review dose and benefit annually. Never combine with opioids without explicit specialist review — additive respiratory depression.
NSAIDs (long-term)Long-term NSAID use for chronic pain: GI risk (gastroprotection with PPI), cardiovascular risk (avoid in CVD), renal risk (eGFR monitoring), blood pressure elevation. Topical NSAIDs have much better risk profile than systemic for localised pain.Topical diclofenac for localised pain (knee, shoulder). Systemic NSAID: shortest duration; PPI co-prescribe; annual cardiovascular and renal review. Avoid in CKD, heart failure, established CVD.
ParacetamolNICE NG193 (2021): do NOT offer paracetamol for chronic primary pain (insufficient evidence of benefit). This surprised many GPs — paracetamol is not harmful in chronic pain, but its long-term efficacy for chronic primary pain is not supported by evidence. It may be appropriate for acute flares or specific secondary pain conditions.For chronic primary pain: discuss de-prescribing paracetamol if inadequate benefit; use for acute flares rather than regular long-term use. For chronic secondary pain (OA, inflammatory conditions): regular use may remain appropriate.
1D — ICE
💡 Why ICE matters in chronic pain — the "dismissed" patient and the medication expectation

Margaret has been told her MRI is normal and she "should be fine" — the most invalidating experience in chronic pain medicine. She attends with low expectations of being heard and high expectations of another dismissal. Before she can accept that exercise and psychological treatment are more effective than morphine, she must feel that her pain has been validated as real. The ICE exploration — particularly identifying her ideas about what is causing the pain and her concerns about being dismissed again — must precede any treatment discussion.

💭 Ideas
"What do you understand about why the pain persists when the MRI was essentially normal? Do you have a sense of what is keeping it going?"
Most patients with chronic primary pain have a structural model ("there must be something wrong in my back") that is incompatible with the biopsychosocial reality. This structural model drives the demand for imaging, surgical opinions, and escalating medication. Understanding the patient's model allows the GP to build a bridge: "the MRI is normal because chronic pain of this type does not show up on a scan — it lives in the nervous system's response to signals, not in the tissue itself."
😟 Concerns
"What worries you most about your pain — is it the pain itself, the fear of something serious being missed, or what will happen to you if it does not improve?"
Two primary concerns in chronic primary pain: (1) "Am I being fobbed off — is something serious being missed?" — must be addressed with explicit red flag exclusion and reassurance; (2) "Will I be in pain for the rest of my life?" — the most catastrophic chronic pain belief; must be corrected with accurate prognostic information and evidence for recovery. The second concern is a target for ACT: learning to live meaningfully despite pain rather than waiting for pain to disappear before living.
🎯 Expectations
"What were you hoping could happen today — medication change, a specialist referral, or something else?"
Margaret is expecting morphine or a stronger opioid. This expectation must be acknowledged before the NICE NG193-guided alternative is offered. "I understand you were hoping for stronger pain relief — let me explain what the evidence shows about what actually works for pain like yours, because the answer might surprise you." The expectation-correction must be respectful, evidence-based, and accompanied by a genuine alternative (exercise + ACT), not a refusal without an offer.
1E — Psychosocial context
😤 Invalidation and the "Normal MRI" Trauma

Being told "your scan is normal — you should be fine" when in severe pain is one of the most invalidating experiences in medicine. It implies the pain is imagined, exaggerated, or manipulated. The accumulated effect of repeated invalidation creates a patient who arrives defensive, angry, and with very low expectations of being understood. Reversing this narrative — "normal MRI means the pain is a nervous system phenomenon, not a structural one — it is equally real, equally serious, and differently treated" — is the most therapeutic act of this consultation.

"I want to acknowledge something: you have been in significant pain for 4 years, and you have been told repeatedly that your scan is normal and you should be better. That experience is frustrating and dismissive — the pain is real, and a normal MRI does not mean it is in your imagination. It means the type of pain you have lives in the nervous system's sensitivity, not in the tissue. That changes how we treat it."
🧠 Pain Catastrophising

Pain catastrophising — the tendency to ruminate about pain, magnify its significance, and feel helpless — is the strongest predictor of chronic pain disability. It is not a personality trait or a sign of weakness. It is a learned cognitive response to repeated, unpredictable pain that has not been adequately explained or managed. ACT and pain-focused CBT are specifically designed to interrupt the catastrophising cycle: changing the relationship with pain rather than the pain itself.

"When the pain is at its worst, what goes through your mind? Do you find yourself thinking things like 'this is never going to get better' or 'the pain must be doing damage'? Those thoughts are a very important part of what keeps the pain so disabling — and they are something we can actually work on."
🚶 Deconditioning and Fear-Avoidance

Margaret has stopped walking — partly because it hurts, partly because she fears it will make things worse. Fear-avoidance is the cycle: fear of pain → avoidance of activity → deconditioning → lower pain threshold → more pain from less activity → more fear and avoidance. This cycle is one of the most powerful perpetuating mechanisms in chronic pain. Exercise — gradually, graded, supported — breaks the cycle. The key cognitive shift: "movement is medicine, not damage."

"I know movement hurts, and I know you are worried about making things worse. But the evidence is clear: for pain of this type, the most effective thing we can do — better than any medication — is to gradually increase movement. Not because it will stop the pain immediately, but because deconditioning is amplifying every signal your nervous system receives."
👤 Identity Loss

Margaret was a teacher — an active, engaged professional. Chronic pain has replaced her professional identity with a pain identity. Much of her daily mental and social life is now organised around her pain: monitoring it, managing it, explaining it, advocating about it. This identity reorganisation maintains the pain and reduces quality of life. ACT specifically addresses the identity shift: reorienting toward values (what matters to me) rather than pain (what prevents me from being who I was).

"What mattered to you before the pain — what did you love doing, what gave you a sense of purpose? I ask because one of the treatments I want to offer is specifically about getting back to the things that matter to you, even if the pain is still present."
💊 Opioid Dependence and the Escalation Trap

Margaret has been on tramadol for 2 years with "incomplete relief." This pattern — long-term opioid with escalating dose requirement and no functional benefit — is the clinical signature of opioid-induced hyperalgesia. The opioid is paradoxically worsening the central sensitisation that is maintaining the pain. Explaining this to the patient without making them feel blamed for taking a prescribed medication requires skill and empathy. "Your brain has adapted to the tramadol in a way that is actually maintaining the pain sensitivity."

"I want to talk about the tramadol honestly. You have been on it for 2 years and it is not giving you good relief. The research shows that long-term opioids like tramadol can sometimes make the nervous system more sensitive to pain over time — not less. That means the tramadol may actually be part of what is keeping the pain so difficult. I would like to discuss a gradual plan to reduce it."
🔮 Prognosis and Possibility

Chronic primary pain is not curable in the sense of eliminating all pain — but it is very manageable. The evidence for exercise and ACT is that 50–70% of patients achieve significant improvement in function and quality of life. The treatment goal is not pain elimination but pain acceptance alongside meaningful living. Many patients describe their lives as fully meaningful and satisfying with reduced but residual pain after effective treatment. Communicating this accurately — not falsely optimistic and not pessimistic — is a key therapeutic act.

"The goal of treatment is not to make you pain-free — though some people do achieve that. The goal is to get you back to living a life that feels meaningful and full, even if some pain is still present. That is achievable. And the treatments that achieve it are not stronger medications."
🎓 SCA Checkpoint — Step 1TasksRelating to OthersGlobal Skills
Key phrases that score
"Your pain is real. A normal MRI means this type of pain lives in the nervous system's sensitivity, not in the tissue. That is equally real, equally serious, and has different — and actually more effective — treatments."
"The tramadol has been on board for 2 years with incomplete relief. The research shows that long-term opioids can actually increase the nervous system's sensitivity to pain over time — this is called opioid-induced hyperalgesia. I would like to discuss a gradual plan to reduce it."
"The most effective treatment for pain of this type is exercise — not because it is easy, but because it directly addresses the nervous system sensitisation that is maintaining your pain. Better than any medication we have."
Deductions
  • Prescribing morphine or escalating opioids — NICE NG193 explicitly recommends against this for chronic primary pain
  • Not validating the pain before explaining the treatment approach
  • Not addressing the "dismissed by previous GPs" experience
  • Not screening PHQ-9 for depression
  • Not identifying pain catastrophising and fear-avoidance
🔴 Red
Morphine prescribed or escalation agreed; pain invalidated ("your MRI is fine"); biopsychosocial model not used; PHQ-9 not done; exercise and ACT not mentioned; opioid-induced hyperalgesia not explained; catastrophising not assessed
🟠 Amber
Pain validated; exercise mentioned but not explained; opioid escalation declined but not explained why; PHQ-9 done; catastrophising not explored; biopsychosocial model mentioned but not explained; tramadol de-prescribing not discussed
🟢 Green
Pain validated first; biopsychosocial model in plain language; OIH explained; exercise as most effective treatment; ACT/CBT introduced; NICE NG193 framework applied; tramadol de-prescribing discussed; catastrophising assessed; PHQ-9; red flags re-screened; ICE all three; closing question
2
Step 2
Triage — Red Flag · Urgent · Routine
collapse
Chronic pain triage separates red flag exclusion (urgent imaging and referral) from NICE NG193-guided management of established chronic primary pain. The most common triage error is offering opioid escalation as a triage response to a pain crisis — this is almost never appropriate for chronic primary pain.
🔴 Urgent — exclude serious pathology

Same-Day to 2 Weeks

Structural or systemic cause must be excluded
  • Cauda equina features999 / Emergency MRI / neurosurgery — saddle anaesthesia, bilateral leg weakness, bladder/bowel dysfunction
  • Night pain + weight loss (>50 years) — malignancyUrgent MRI spine; 2WW; FBC/ESR/LDH/protein electrophoresis
  • Fever + focal neurology + back pain — spinal infectionUrgent MRI; blood cultures; FBC/CRP; emergency admission if septic
  • Active suicidal ideation with planSame-day crisis team; adjust opioid prescribing (monthly supply only) if risk present
🟠 Specialist / Secondary Care

Weeks

Complex or refractory
  • Refractory chronic pain despite exercise + ACT + adequate medicationPain clinic / multidisciplinary pain management programme (MPMP)
  • Neuropathic pain — specialist assessment neededNeurology; pain medicine; capsaicin patch (specialist-initiated)
  • Opioid tapering requiring specialist supportCommunity addiction services; pain clinic shared care
🟢 Chronic Primary Pain — NICE NG193

Primary Care

Biopsychosocial management
  • Established chronic primary painExercise (graded, supervised); ACT or CBT (NHS Talking Therapies pain pathway); self-management programme; social prescribing; address comorbid depression
  • Opioid de-prescribing discussionIf on long-term opioids with no functional benefit: 10% taper every 2–4 weeks; pain psychology alongside
🎓 SCA Checkpoint — Step 2Tasks
Triage rationale
"Before anything else, I want to make sure there are no new symptoms that need urgent investigation — any new weakness in your legs, any numbness in your saddle area, any problems with your bladder or bowel? I need to ask these specifically even though you have had back pain for years."
Deductions
  • Not re-screening red flags at a chronic pain consultation
  • Escalating opioids without explicitly documenting red flag exclusion and NICE NG193 framework
3
Step 3
Examination — Functional Assessment
collapse
Chronic pain examination serves two purposes: red flag exclusion and functional baseline. The examination in chronic primary pain rarely reveals new structural pathology — but neurological examination excludes progressive myelopathy, and observational functional assessment (how the patient moves, sits, rises) provides a baseline for measuring rehabilitation progress.
ExaminationWhy it mattersFinding changes managementChanges?
Neurological examination (lower limbs)Excludes myelopathy and cauda equina features: power (L3–S2 myotomes); reflexes (knee jerk L3/4; ankle jerk S1); sensation (dermatomal); Babinski (upper motor neurone sign — suggests cord involvement). Straight-leg raise: radiculopathy if positive (<45 degrees, radiating below knee).New neurological deficit → urgent MRI regardless of chronic pain history. Progressive deficit → emergency referral. Chronic fixed deficit without change → document as baseline.YES — red flag exclusion mandatory
Musculoskeletal assessmentRange of movement (ROM); tenderness; muscle spasm; gait. For fibromyalgia: widespread allodynia on palpation (tender points). For chronic back pain: paraspinal muscle spasm, Waddell signs (non-organic signs: distraction testing, simulation testing, over-reaction). Waddell signs do not mean malingering — they indicate significant psychosocial overlay requiring the biopsychosocial approach.Multiple Waddell signs (>3) → high psychosocial complexity; pain clinic or MPMP referral. Fibromyalgia tender points → confirm diagnosis; duloxetine + exercise.YES — Waddell signs change management pathway
Functional observationHow does the patient move from waiting room to consulting room? Do they exhibit pain behaviour (grimacing, guarding, excessive movement limitation) disproportionate to reported pain? Functional inconsistency is not the same as malingering — it is a sign of significant psychosocial overlay. Distraction testing: can the patient achieve more function when distracted from the pain focus?Significant functional inconsistency → psychosocial complexity; ACT/CBT referral urgently; physiotherapy with pain psychologist. Consistent functional limitation → graded exercise and physio.Context
BP and weight (opioid side effects)Long-term opioid use: weight gain (especially tramadol); blood pressure effects; opioid-related hormonal changes (hypogonadism from opioid-induced pituitary suppression — fatigue, sexual dysfunction, low mood). Baseline for medication review.Opioid-related weight gain → reinforce de-prescribing; exercise programme. Hypogonadism signs → testosterone/oestrogen screen; endocrinology if confirmed.Context — opioid review
🎓 SCA Checkpoint — Step 3Tasks
Examination rationale
"I would like to check your reflexes and sensation briefly — to make sure there is nothing new that needs urgent attention. I will also have a quick look at how you are moving."
Deductions
  • Missing a new neurological deficit in a patient with pre-existing chronic pain
4
Step 4
Investigations — Targeted, Not Routine
collapse
NICE NG193 does not recommend routine imaging or blood tests for chronic primary pain. Investigations are targeted at red flag exclusion, secondary cause identification (inflammatory, metabolic, malignant), and medication safety monitoring. Unnecessary imaging in chronic pain reinforces structural illness beliefs and can harm — patients who have an MRI showing minor degenerative changes attribute their pain to these findings and seek surgery that will not help.
InvestigationWhen indicatedWhat result changes management
PHQ-9 + GAD-7 — mandatory at every consultationDepression in 40–60% of chronic pain patients. Mandatory rating scales at every chronic pain consultation — not just at first presentation. Antidepressant treatment of comorbid depression significantly improves pain outcomes. PHQ-9 item 9: suicidal ideation screen. GAD-7: anxiety amplifying pain sensitisation.PHQ-9 ≥10 → duloxetine (pain + depression); CBT. PHQ-9 ≥15 + suicidal ideation → crisis assessment; opioid prescribing review (monthly supply). GAD-7 ≥10 → anxiety management alongside pain pathway.
FBC + CRP + ESR — if inflammatory or systemic cause suspectedElevated inflammatory markers → consider inflammatory arthritis (RA, ankylosing spondylitis, psoriatic arthritis), malignancy, infection. Anaemia (common in inflammatory conditions; can amplify fatigue and pain perception). NOT routine for chronic primary pain — only if clinical suspicion of inflammatory cause.Elevated CRP/ESR → rheumatology referral; inflammation screen (ANA, ANCA, RF, anti-CCP, HLA-B27); MRI of relevant joints. Normal → chronic primary pain more likely; biopsychosocial pathway.
Thyroid function — if fatigue + widespread painHypothyroidism: widespread musculoskeletal pain, fatigue, cognitive slowing — clinical mimic of fibromyalgia. Must be excluded in any new fibromyalgia-like presentation. Also relevant in chronic pain management: hypothyroidism worsens pain sensitivity and depression.Hypothyroidism → levothyroxine; reassess pain after normalisation. Normal → fibromyalgia pathway.
eGFR / LFTs — before and during analgesic prescribingNSAIDs: contraindicated in eGFR <30; use with caution eGFR 30–60. Gabapentinoids: dose adjustment in renal impairment. Tramadol: accumulates in CKD; reduce dose. Paracetamol: dose reduction in severe hepatic impairment. Annual renal and hepatic monitoring in patients on long-term analgesics.CKD → avoid NSAIDs; reduce tramadol/gabapentinoid doses; consult BNF. Hepatic impairment → reduce paracetamol; avoid NSAIDs.
MRI — only for red flag symptomsNOT indicated for routine chronic primary pain without red flags. Indication: new neurological deficit; suspected malignancy; suspected spinal infection; cauda equina features. Incidental findings on MRI (disc dehydration, facet arthropathy) are ubiquitous in the population and often increase patient anxiety without changing management. NICE NG193: routine imaging in chronic primary pain is not recommended.Red flag present → urgent MRI; appropriate referral. No red flags → MRI not indicated; document reasoning to address patient expectation for scanning.
🎓 SCA Checkpoint — Step 4Tasks
Investigation rationale
"I am not going to request a new MRI today — the previous one two years ago was essentially normal, and another scan is unlikely to change management unless new neurological symptoms develop. What I do want to do is a mood questionnaire, because treating depression often significantly helps with chronic pain."
Deductions
  • Ordering MRI for established chronic primary pain without new red flags — may reinforce structural illness belief
  • Not completing PHQ-9 at a chronic pain consultation
5
Step 5
Diagnosis — Biopsychosocial Model in Plain Language
collapse
Explaining chronic primary pain using the biopsychosocial model — in accessible language — is the most important clinical intervention in this consultation. A patient who understands why their pain persists despite a normal MRI is a patient who can accept that exercise and psychological treatment are more effective than morphine.
🗣️ Explaining Chronic Pain — the Nervous System Model

"Think of your pain system like a smoke alarm. Normally, the smoke alarm goes off when there is smoke — that is useful, it keeps you safe. After your disc problem, your pain system had a genuine reason to fire — there was an injury. But sometimes, after prolonged pain, the alarm system becomes oversensitive. It starts firing even when there is nothing actually dangerous — it is now responding to tiny signals as if they are major threats. A normal MRI does not mean there is nothing wrong — it means the problem is in the alarm system's sensitivity, not in the structure it is protecting. The good news is that the alarm system can be recalibrated. But the treatments that recalibrate it are not the same as the treatments for a structural injury — and stronger painkillers do not turn down an oversensitive alarm."

💬 Why stronger opioids will not help and may harm

"I just need something stronger — if the pain was properly controlled I could get on with my life."
"I understand why that makes sense. But there is an important piece of research I want to share with you: for pain of this type — where the nervous system is oversensitised rather than where there is ongoing tissue damage — opioids actually make the nervous system more sensitive over time, not less. This is called opioid-induced hyperalgesia. It is one of the reasons the tramadol has been getting less effective over time. Morphine would produce the same effect: short-term relief, then escalating tolerance, then increased pain sensitivity. The research shows that patients who taper off opioids and do the exercise and psychological programme end up with less pain and more function than patients who escalate the opioid dose. I know that is the opposite of what you expected to hear — but that is what the evidence shows."

A — Chronic Primary Pain
NICE NG193 pathway
Chronic Primary Pain: Pain as the primary condition; no identifiable underlying pathology; central sensitisation; nociplastic pain mechanism; encompasses fibromyalgia, widespread pain, non-specific back pain
Mechanism: Central sensitisation — reduced descending inhibition; increased spinal cord excitability; amplified peripheral signals; neuroinflammation
B — Chronic Secondary Pain
Treat underlying cause

Neuropathic Pain

Post-herpetic neuralgia; diabetic neuropathy; CIPN; spinal stenosis. Treat with duloxetine, amitriptyline, gabapentinoid (note: NOT for primary pain).

Inflammatory (RA, SpA)

Elevated inflammatory markers; synovitis; rheumatology; DMARDs.

Cancer Pain

WHO analgesic ladder applies; opioids appropriate; specialist oncology pain service.

C — Do Not Miss
Urgent exclusion

Cauda Equina

Saddle anaesthesia + bladder/bowel → 999; emergency MRI.

Vertebral Malignancy / Infection

Night pain + systemic features → urgent MRI; cancer/infection screen.

🎓 SCA Checkpoint — Step 5TasksRelating to Others
Explaining chronic pain
"The diagnosis is chronic primary pain — which means the pain is being maintained by the nervous system's oversensitivity rather than by ongoing tissue damage. Your pain is real — it is just a different type of real than shows up on a scan, and it needs different treatment."
Deductions
  • Not explaining why the MRI being normal does not mean the pain is imagined
  • Not explaining OIH when declining opioid escalation
6
Step 6
Referral — Pain Clinic · MPMP · NHS Talking Therapies Pain Pathway
collapse
NICE NG193 primary care pathway first — specialist referral for refractory cases or specific interventions. Most chronic primary pain is managed in primary care with exercise, ACT/CBT, and comorbidity treatment. Pain clinic referral is for refractory cases, complex opioid situations, and consideration of interventional techniques. Multidisciplinary Pain Management Programmes (MPMP) have the strongest evidence for severe, refractory chronic primary pain.
ReferralUrgencyWhat to includeWhat NOT to do
NHS Talking Therapies — Pain-Focused ACT or CBTRoutine (can self-refer)Diagnosis: chronic primary pain. Pain history, duration, previous treatments. PHQ-9 and GAD-7 scores. Request: ACT for chronic pain or pain-focused CBT; not generic counselling. PCS (Pain Catastrophising Scale) score if available.Do NOT refer to NHS Talking Therapies as a substitute for physical exercise — both are needed. Do NOT refer as "depression and pain" if the primary problem is the pain — specify pain-focused psychological therapy.
Physiotherapy — Supervised Exercise ProgrammeRoutineDiagnosis; functional impairment; current pain level. Request: graded exercise programme for chronic primary pain; not passive treatment (massage, ultrasound, acupuncture alone) but active exercise-based rehabilitation. Specify: pain neurophysiology education (PNE) alongside exercise is recommended by NICE NG193.Do NOT refer for passive physiotherapy alone (massage, manipulation) — these do not address central sensitisation and may reinforce the structural model. Active exercise is the therapeutic component.
Pain Clinic — Specialist Chronic Pain ServiceRoutine (complex cases)Reserve for: refractory chronic primary pain after adequate exercise + ACT + first-line pharmacotherapy; complex opioid tapering requiring specialist support; consideration of spinal cord stimulation (SCS) for failed back surgery syndrome or neuropathic pain. Include medication list, functional impact, previous treatments, PHQ-9.Do NOT refer to pain clinic expecting medication escalation — pain clinics increasingly follow NICE NG193 and provide MDT approaches, not just stronger medication. Premature specialist referral delays GP-led biopsychosocial management that may be more effective.
Multidisciplinary Pain Management Programme (MPMP)Routine (severe refractory)Severe, refractory chronic primary pain with significant disability; high catastrophising; multiple medication trials. MPMP integrates psychology, physiotherapy, occupational therapy, and medicine in a structured residential or day-programme format. Best evidence for severe chronic primary pain — superior to any single intervention.Not appropriate as first-line — GP should have tried exercise, ACT, and medication optimisation first. Requires patient motivation and functional capacity for the intensive programme.
🎓 SCA Checkpoint — Step 6Tasks
Referral plan
"I am making two referrals today: one to physiotherapy for a supervised graded exercise programme — this is the most evidence-based treatment we have for your pain; and one to the NHS Talking Therapies pain psychology service for a therapy called ACT — acceptance and commitment therapy — which specifically helps with chronic pain."
Deductions
  • Referring to passive physiotherapy (massage, manipulation) rather than active exercise-based rehabilitation
  • Not mentioning pain-focused psychological therapy (ACT/CBT) as part of the management plan
7
Step 7
Management — NICE NG193 · Exercise · ACT · Opioid Tapering · Pharmacology · Psychosocial · Follow-Up
collapse
7A — Address expectations: "You came for stronger medication; I am offering something that works better"
🤝
The most difficult consultation task: declining medication escalation while offering a genuinely better alternative
1
Validate — the experience of inadequate treatment

4 years of inadequate pain relief, being told her scan is normal, and feeling dismissed by previous consultations. This is a genuine failure of healthcare, not a personality problem. Acknowledging it explicitly — without defensively justifying previous clinicians — creates the foundation for honest treatment discussion.

"I want to acknowledge something: 4 years is a long time to be in significant pain, and not having the right treatment for that long is genuinely a failure on the healthcare system's part — not yours. The type of pain you have has traditionally been undertreated because we did not have the right tools. I want to change that today."
2
Explain — why morphine will not work and exercise will

The explanation must be specific, evidence-based, and non-dismissive. The OIH mechanism and the neuroplasticity evidence for exercise must both be named. The patient is intelligent (retired teacher) and will respond to accurate information — not to platitudes about "relaxation" and "positive thinking."

"The research on chronic pain like yours is clear: opioids become progressively less effective over time and increase pain sensitivity. Exercise — even small amounts, gradually — does the opposite. It directly reduces the nervous system's hypersensitivity through mechanisms that no medication can replicate."
3
Offer — a specific, achievable starting point

Do not send the patient away with a general recommendation to exercise — identify one specific, achievable activity. Hydrotherapy, aquatic exercise, gentle walking programme, tai chi, yoga — all have evidence. The first step must be small enough to succeed. Success rebuilds self-efficacy; self-efficacy reduces catastrophising.

"I am not asking you to run a marathon. The evidence is that even a 10-minute walk, three times a day, started today, produces measurable improvement in chronic pain within 6 weeks. Let us identify something that feels possible and build from there."
Key principle: The consultation is a success if the patient leaves understanding why exercise works better than opioids for her pain, feeling that her pain has been validated, and with one achievable action to take today. It is a failure if she leaves with a new opioid prescription and no understanding of why her current approach is not working.
7B — Treatment goals
Treatment goals
Exercise programme started: specific activity, specific frequencyACT / CBT pain pathway referral made today Tramadol taper plan agreed (10% / 2–4 weeks)PHQ-9 documented; duloxetine for depression + pain Biopsychosocial model explained and acceptedRed flags re-screened; MRI not ordered (appropriate) Pain catastrophising identified; ACT target named4-week follow-up: exercise progress; PHQ-9 trend; tramadol taper
Key messages
"NICE NG193 (2021): exercise is more effective than any medication for chronic primary pain. The mechanism is direct — exercise reduces the nervous system's sensitivity, improves descending inhibitory pathways, and produces endogenous opioids. No tablet does all of that."
"The treatment goal is not pain elimination — that is not what the evidence offers. The treatment goal is a life that is full and meaningful, with the pain present but not defining. That is achievable."
7C — Non-medication management: the evidence base
NICE NG193 (2021) explicitly recommends exercise and ACT/CBT as first-line for chronic primary pain. These are not consolation prizes offered when "real treatment" is refused. They are the most effective interventions available for this condition — with a better evidence base than any analgesic for chronic primary pain.
🏃
Graded Exercise — Any Modality
NICE NG193 first-line; start small, build gradually
Mechanism

Exercise directly reduces central sensitisation through multiple mechanisms: endogenous opioid release (endorphins); noradrenergic and serotonergic pathway activation (descending inhibition); neuroplastic changes in spinal cord excitability; reduced neuroinflammation; improved sleep (which further reduces sensitisation); improved mood (antidepressant effect). No analgesic achieves all of these simultaneously.

Evidence

Cochrane meta-analysis: aerobic exercise reduces pain intensity and improves function in chronic primary pain; effect size comparable to SSRI for depression. NICE NG193: offer supervised group or individual exercise. Any modality (walking, swimming, cycling, yoga, tai chi) is effective — the key is gradual progression and consistency. Supervised exercise (physio) is more effective than self-directed for most patients initially.

Largest single evidence base in chronic primary pain; any modality
🧘
ACT — Acceptance and Commitment Therapy
NICE NG193 first-line psychological therapy
Mechanism

ACT does not aim to reduce pain intensity. It aims to reduce the suffering caused by pain by changing the patient's relationship with it. Core processes: acceptance (willingness to experience pain without struggle); defusion (seeing painful thoughts as events, not facts: "I am noticing the thought that I will never get better" rather than "I will never get better"); valued action (committed engagement with what matters, despite pain). Reduces catastrophising and increases psychological flexibility.

Why ACT rather than standard CBT

Standard CBT for pain: challenges the content of catastrophic thoughts ("is this thought realistic?"). ACT: changes the relationship with the thoughts ("this thought is present; it is not a fact I must act on"). Both are effective; ACT has slightly stronger evidence for acceptance-related outcomes and for patients who have already tried CBT without success.

Reduces disability and catastrophising; improves quality of life even with pain present
📚
Pain Neurophysiology Education (PNE)
NICE NG193 recommended alongside exercise
Evidence

Pain Neurophysiology Education (PNE): systematic patient education about the science of chronic pain — how central sensitisation works, why normal MRI is compatible with significant pain, why exercise helps and opioids eventually worsen it. Cochrane: PNE + exercise is more effective than exercise alone. PNE directly changes the structural illness model and reduces catastrophising before therapy begins.

Practical

The GP consultation is the first opportunity for PNE. Resources: "Explain Pain" (Butler and Moseley — the standard patient education book); NHS Chronic Pain Self-Management resources; Live Well with Pain (livewellwithpain.co.uk). The smoke alarm analogy used in Step 5 is a core PNE metaphor.

PNE + exercise superior to exercise alone; reduces catastrophising
😴
Sleep Management
Sleep and pain: vicious cycle; must be broken
Mechanism

Pain disrupts sleep; poor sleep reduces descending inhibitory pain pathways (noradrenergic and serotonergic); reduced inhibition amplifies pain signals; more pain disrupts sleep further. Treating the sleep disorder in chronic pain is a direct pain-modulating intervention, not just comfort management. CBT-I for insomnia in chronic pain has evidence for both sleep and pain improvement.

Practical

Sleep hygiene (consistent wake time; stimulus control; no screens in bed). Low-dose amitriptyline 10mg nocte: evidence specifically for improved sleep in chronic pain and fibromyalgia. Not recommended for long-term use in primary care but can be useful short-term bridge while exercise and ACT take effect.

Sleep improvement reduces central sensitisation; improves pain control
🤝
Social Prescribing and Self-Management
Isolation worsens pain; community connection helps
Evidence

Social isolation is a significant chronic pain amplifier — it increases central sensitisation through stress pathway activation and removes positive meaning from daily life. Peer support groups for chronic pain (Action on Pain; Pain Concern) reduce catastrophising and improve function. Social prescribing (link worker referral to community activities) is a NICE NG193-endorsed component of management.

Practical

Link worker referral for community activities. Pain support groups. Livewellwithpain.co.uk (online chronic pain self-management resource). Activities chosen around patient values — not generic "just get out of the house" advice. Return to meaningful activities (teaching, reading groups, volunteering) is an ACT target.

Social connection reduces central sensitisation; improves engagement with treatment
💊
Opioid Tapering — The Most Impactful Pharmacological Intervention
10% reduction every 2–4 weeks
Mechanism

Opioid-induced hyperalgesia (OIH): chronic opioids down-regulate descending inhibitory pathways, up-regulate NMDA receptor excitability, and produce tolerance at mu-opioid receptors — net effect is increased pain sensitivity. Tapering opioids allows neuroplastic recovery of pain-inhibitory pathways. Most patients who complete opioid taper report equivalent or improved pain control at lower opioid dose or no opioid.

Process

10% dose reduction every 2–4 weeks. Slower if anxiety or dependence features. Pain psychology mandatory alongside taper. Buprenorphine patch as transition if significant dependence. Never abrupt cessation. Warn about temporary pain increase during taper (expected; not relapse). Document shared decision-making explicitly — patient agreement is essential.

OIH reversal: most patients improve pain control after taper
7D — Prescribing guide: NICE NG193
NICE NG193 (2021) — landmark changes to chronic pain pharmacotherapy: Do NOT offer paracetamol, NSAIDs, antidepressants, or opioids as primary pharmacological treatment for chronic primary pain. The exception: if any of these are already providing good benefit with acceptable side effects, continue them. The key principle: medication de-escalation for chronic primary pain, combined with exercise and ACT.
Depression comorbidity: Duloxetine or Amitriptyline

Duloxetine 30mg OD → 60mg OD; or low-dose Amitriptyline 10mg nocte

  • Duloxetine: SNRI; licensed for diabetic neuropathic pain and fibromyalgia; significant evidence for pain + depression comorbidity. Not NICE NG193 recommended as first-line for undifferentiated chronic primary pain but appropriate when depression is comorbid.
  • Low-dose amitriptyline 10mg nocte: evidence specifically for fibromyalgia sleep and pain (at 10mg — much lower than antidepressant doses). Not to be routinely prescribed for non-specific chronic pain per NICE NG193.
Neuropathic Pain Component: Duloxetine or Gabapentinoid

Gabapentin/Pregabalin ONLY for confirmed neuropathic pain — NOT primary pain

  • NICE NG193: do NOT offer gabapentinoids for chronic primary pain — high-yield exam point
  • Gabapentinoids ARE appropriate for confirmed neuropathic pain (diabetic neuropathy, post-herpetic neuralgia, CIPN) but must not be confused with chronic primary pain treatment
  • Class C controlled drugs since 2019; significant dependence and misuse potential; additive respiratory depression with opioids
NICE NG193: Do NOT Start For Chronic Primary Pain
  • Opioids (tramadol, codeine, morphine, oxycodone) — cause OIH; worsen long-term outcomes; do not start; taper if already prescribed
  • Gabapentinoids (gabapentin, pregabalin) — no evidence for chronic primary pain; significant harms; do not start
  • Paracetamol — insufficient evidence of benefit in chronic primary pain; de-prescribe if no benefit
  • NSAIDs (long-term) — insufficient evidence for chronic primary pain; significant CV, GI, renal risks with long-term use
7E — Medication selector

Select clinical scenario — see drug cards below

NICE NG193 pharmacological guide
NICE NG193 (2021): Exercise + ACT first-line for chronic primary pain. Pharmacology by scenario: Depression + pain: duloxetine 30→60mg OD (SNRI; evidence for pain + depression). Neuropathic pain only: pregabalin/gabapentin OR duloxetine OR amitriptyline. Fibromyalgia: duloxetine + exercise; amitriptyline 10mg nocte for sleep. Opioid tapering: 10% reduction every 2–4 weeks; buprenorphine patch as bridge. Sleep: CBT-I; amitriptyline 10mg nocte (short-term). Localised pain: topical diclofenac gel (far safer than systemic NSAID). DO NOT START for chronic primary pain: opioids, gabapentinoids, routine paracetamol, long-term NSAIDs.
7F — Drug reference cards
Duloxetine — Chronic Pain + Depression
Cymbalta / generic 30mg / 60mg capsules · SNRI · Licensed: diabetic neuropathic pain; fibromyalgia; GAD; depression
✓ Depression + pain comorbidity
Depression + pain; neuropathic; fibromyalgia30mg OD × 2 weeks → 60mg OD
✓ When appropriate
Chronic pain + comorbid depression (PHQ-9 ≥10) — addresses both; SNRI mechanism inhibits noradrenergic and serotonergic reuptake, enhancing descending inhibitory pain pathways
Fibromyalgia — licensed in EU; evidence-based for pain and fatigue
Diabetic peripheral neuropathic pain — NICE-licensed indication; significant evidence base
✗ NICE NG193 caveat
NICE NG193 does NOT recommend duloxetine as first-line for undifferentiated chronic primary pain — it is appropriate when depression or neuropathic pain is comorbid, not as a universal chronic pain treatment
Discontinuation syndrome: taper slowly when stopping; do not stop abruptly
⚠ Side effects
Nausea (give with food; start at 30mg), insomnia, sweating, dry mouth, constipation, increased BP. Sexual dysfunction. Discontinuation syndrome — taper over ≥4 weeks.
🔬 Monitor
PHQ-9 at 4 and 12 weeks. Pain intensity (VAS/NRS) and function. BP (modest increase possible). eGFR (avoid if <30). Discontinuation plan documented before initiating.
💬 Counselling

"This tablet treats both the low mood and the pain by affecting the pathways that regulate both in the brain and spinal cord. Start at 30mg for 2 weeks to help with tolerability, then increase to 60mg. Take it in the morning with food. It takes 4–6 weeks to see the full effect. Do not stop it suddenly — we reduce it gradually."

Duloxetine: NICE NG193 framework — appropriate for chronic pain when depression or neuropathic pain is comorbid; NOT first-line for undifferentiated chronic primary pain without these features. SNRI mechanism enhances descending inhibitory pain pathways. Discontinuation syndrome: always taper.

Low-Dose Amitriptyline — Pain and Sleep
Amitriptyline 10mg / 25mg tablets · TCA · Low dose (10mg) is analgesic; high dose (>75mg) is antidepressant
✓ Fibromyalgia sleep/pain; neuropathic
Fibromyalgia; neuropathic; nocte10mg nocte → titrate cautiously (max 75mg for pain)
✓ Evidence-based indications
Fibromyalgia: evidence for sleep improvement and pain reduction at 10–25mg nocte — one of the few pharmacological interventions for fibromyalgia with consistent RCT evidence at low dose
Neuropathic pain: evidence-based (NICE NG173 recommends amitriptyline for neuropathic pain alongside duloxetine and gabapentinoids)
Chronic pain + significant sleep disruption: 10mg nocte improves sleep quality and indirectly improves pain through sleep-pain cycle
✗ Avoid if
QTc prolongation; recent MI; cardiac arrhythmia; MAOI within 14 days; urinary retention; acute angle-closure glaucoma
Elderly: anticholinergic effects (falls, confusion, urinary retention); use with extreme caution or avoid. NICE NG193: not recommended for chronic primary pain routinely — evidence base is for fibromyalgia and neuropathic pain specifically.
⚠ Side effects
Anticholinergic (dry mouth, constipation, urinary retention, blurred vision). Morning grogginess at 25mg+. Weight gain. QTc prolongation (check ECG if cardiac risk factors before doses >50mg). Sedation (therapeutic nocte).
🔬 Monitor
Sleep quality (direct outcome target). Pain intensity. ECG before doses >75mg or if cardiac risk. Annual review of ongoing need. Falls assessment in elderly. Do not combine with other QTc-prolonging drugs without ECG review.
💬 Counselling

"Take this at night — 10mg is a very low dose, much lower than when it is used for depression. At this dose it helps with sleep quality and with the pain. You will notice the dry mouth — drinking water helps. Do not drive if you feel drowsy the next morning."

Low-dose amitriptyline (10mg nocte) has specific evidence for fibromyalgia and neuropathic pain. NICE NG193: not recommended for undifferentiated chronic primary pain routinely. More sedating than at antidepressant doses — night-time use is the clinical application. ECG before higher doses. Anticholinergic effects limit use in elderly.

Pregabalin / Gabapentin — Neuropathic Pain ONLY
Pregabalin 25–300mg BD / Gabapentin 300–900mg TDS · Class C CD since 2019
⚠ NEUROPATHIC ONLY — not primary pain
Neuropathic pain; Class C CD; specific indicationPregabalin: 25–75mg BD → max 300mg BD (renal adjusted)
⛔ NICE NG193 restriction — high-yield exam point
NICE NG193 (2021): do NOT offer gabapentinoids (pregabalin, gabapentin) for chronic primary pain. This is an explicit NICE prohibition with significant clinical and exam relevance — many GPs still prescribe these for non-specific back pain and fibromyalgia, which is against the current guideline.
Appropriate ONLY for: confirmed neuropathic pain (diabetic neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathy, central post-stroke pain)
✓ When appropriate
Diabetic peripheral neuropathy (NICE NG193: duloxetine first; gabapentinoid second)
Post-herpetic neuralgia (significant evidence; first-line alongside amitriptyline)
Central neuropathic pain after spinal cord injury (pregabalin licensed)
⚠ Side effects
Dizziness and somnolence (most common — dose-related; titrate slowly). Falls (significant risk in elderly). Cognitive impairment. Respiratory depression with opioids (additive — significant clinical risk; never combine without explicit review). Class C CD since April 2019 — misuse potential; prescribe carefully.
🔬 Monitor
Falls risk (particularly elderly). Renal function (dose reduction in CKD). AUDIT-C (gabapentinoid misuse risk in alcohol misuse population). Annual review of benefit vs harm. Taper slowly when stopping — withdrawal syndrome.
💬 Counselling

"This tablet is specifically for the nerve pain component — the burning and shooting sensations. It can cause dizziness and drowsiness at first, especially when you stand up. Start slowly and increase only as the dizziness settles. Do not drive until you know how it affects you."

High-yield exam point: NICE NG193 explicitly prohibits gabapentinoids for chronic primary pain. They are only appropriate for confirmed neuropathic pain. Class C CD since 2019. Respiratory depression with opioids (additive). Renal dose adjustment essential. This is one of the most commonly examined NICE NG193 points in SCA.

Tramadol De-Prescribing — Opioid Taper Plan
Tramadol 50mg / 100mg / 150mg / 200mg · Opioid · NICE NG193: do not start; taper if already prescribed
✓ De-prescribing plan
De-prescribing; 10% taper; OIHReduce by 10% every 2–4 weeks; never abrupt
⚠ NICE NG193 — do not start opioids for chronic primary pain
NICE NG193 (2021): opioids should not be started for chronic primary pain. If already prescribed, discuss tapering with the patient, explaining OIH and the evidence for better outcomes with lower opioid burden.
Opioid-induced hyperalgesia: long-term opioids increase NMDA receptor excitability, down-regulate descending inhibitory pathways, and produce tolerance — net effect is increased pain sensitivity despite opioid use. Explains why tramadol is "not working like it used to."
✓ Tapering principles
Reduce by 10% of current dose every 2–4 weeks (slower if significant anxiety or dependence features)
Never abrupt cessation — withdrawal syndrome (anxiety, sweating, agitation, diarrhoea, muscle aches)
Pain psychology (ACT) must be initiated alongside taper — the taper alone without psychological support has high failure rate
Buprenorphine patch as transition agent if significant opioid dependence — partial agonist; more stable analgesic level; allows opioid taper without full withdrawal
⚠ Expected during taper
Temporary pain increase in first 2–4 weeks of taper (expected — OIH reversal is not immediate; pain sensitivity briefly increases before improving). Withdrawal symptoms if tapering too rapidly. Anxiety about pain — ACT target.
🔬 Monitor
Pain VAS/NRS at each appointment. Function (most important: has function improved despite pain?). Withdrawal symptoms. PHQ-9 (depression may temporarily worsen during opioid taper). AUDIT-C (alcohol substitution risk during taper).
💬 Counselling

"I want to explain why I am recommending reducing the tramadol rather than increasing it. The research shows that long-term opioids can actually increase the nervous system's sensitivity to pain over time — this is called opioid-induced hyperalgesia. The tramadol is part of what is keeping your pain difficult. Most patients who complete a gradual reduction end up with equal or better pain control without the opioid. The reduction will be very slow and I will support you throughout."

NICE NG193: opioids should not be started for chronic primary pain; if already prescribed, discuss tapering. OIH must be explained to justify the taper to the patient. 10% reduction every 2–4 weeks; never abrupt; pain psychology alongside. Documenting shared decision-making is essential — patient must understand and agree to the plan.

Topical Diclofenac — Localised Pain
Voltarol Gel 1% / 2.32% · Apply 3–4× daily · OTC and prescription available
✓ Localised pain; better safety profile
Localised; safer than systemic NSAIDApply 2–4g (2–4× daily) to affected area
✓ When appropriate
Localised musculoskeletal pain (knee OA, shoulder pain, localised back pain) — topical achieves local tissue concentrations with minimal systemic absorption
NICE NG193: topical NSAIDs are preferred over systemic for localised pain — significantly safer cardiovascular, GI, and renal profile
Can be used in patients with mild CKD where systemic NSAIDs are avoided (topical absorption very low)
✗ Cautions
Not for widespread pain (systemic NSAIDs would then be needed — assess CV/renal/GI risk). Avoid broken skin; open wounds. Photosensitivity at application site. Not in pregnancy (third trimester).
⚠ Side effects
Local skin reactions (erythema, pruritus). Rare systemic absorption (but much lower than oral NSAID). Photosensitivity at application site.
🔬 Monitor
Pain response at 4 weeks. Skin condition at application site. Annual review of continued need. If inadequate response: consider systemic NSAID trial with full GI/CV/renal risk assessment.
💬 Counselling

"Apply a small amount directly to the painful area 3–4 times a day. Rub it in gently. Wash your hands afterwards. If you are going to be outside in sunshine, cover the area — it can make the skin more sensitive to the sun. It should start helping within a few days of regular use."

NICE NG193 preferentially recommends topical NSAIDs over systemic for localised pain. Much safer profile: negligible cardiovascular, GI, and renal effects compared with oral NSAIDs. Appropriate even in mild CKD where systemic NSAIDs are avoided. OTC availability (Voltarol Gel) makes it accessible.

Capsaicin — Topical for Localised / Neuropathic Pain
Low-strength: 0.025–0.075% cream (OTC) · High-strength: 8% patch (Qutenza — specialist only)
✓ Localised / neuropathic; topical
OTC low-strength; specialist 8% patchLow: apply 3–4× daily; 8% patch: specialist procedure
✓ When to use
Low-strength capsaicin (0.025–0.075% cream): OTC for localised musculoskeletal pain; evidence for osteoarthritis pain; neuropathic pain as adjunct
High-strength capsaicin 8% patch (Qutenza): specialist-initiated for peripheral neuropathic pain (post-herpetic neuralgia, DPNP, HIV neuropathy); a single application lasts up to 3 months; requires anaesthetic pre-treatment; applied in specialist clinic
Mechanism: depletes substance P in nociceptive fibres — reduces peripheral pain signal transmission
✗ Cautions
Initial burning sensation (intense with 8% patch; milder with low-strength) — warn patient; will reduce after first few days. Avoid eyes, mucous membranes, broken skin. Gloves when applying 8% patch.
⚠ Side effects
Burning sensation at application (expected; therapeutic). Erythema. Sneezing if inhaled. Qutenza 8% patch: significant burning during application; transient increase in blood pressure; requires specialist facility.
🔬 Monitor
Pain response at 4 weeks (low-strength). Qutenza: specialist review at 3 months for re-application decision. Skin condition.
💬 Counselling

"When you first use this cream it will feel warm or burning — that is expected and means it is working. The burning reduces over the first few days. Use it 3–4 times a day. Wash your hands immediately afterwards and never touch your eyes. It works by reducing the pain signal from the area over time."

Low-strength capsaicin is OTC and appropriate for localised pain; Qutenza 8% patch is specialist-initiated for peripheral neuropathic pain. The burning-on-application is expected and therapeutic — warn the patient to avoid premature discontinuation. NICE NG193: topical agents preferred over systemic for localised pain.

7G — Psychosocial impact of chronic pain
🫂
Chronic pain — the identity condition: loss, isolation, and the long wait for someone to believe you
Chronic pain does not just hurt — it dismantles identities, fractures relationships, isolates people from social life and meaningful activity, and deposits them in a healthcare system that has historically dismissed the reality of their experience as "functional," "psychosomatic," or "drug-seeking." The patient who arrives having been told their MRI is normal, that they should be better, and that the pain must be exaggerated has experienced a profound medical invalidation. The GP who addresses both the clinical reality and this human experience simultaneously is the one who makes a difference.
👤
Identity Loss

Margaret was a teacher — active, engaged, purposeful. Chronic pain has progressively stripped her professional role, her physical activities, her social engagements, and her self-concept. Pain has become her identity. ACT specifically addresses this: the treatment is not about reducing pain but about re-engaging with values and meaningful activity alongside pain.

"What mattered to you before the pain — what gave you a sense of who you are? Because one of the treatments I want to offer specifically helps people return to the things that matter to them, even if the pain is still there."
💔
Relationship Impact

Chronic pain profoundly affects relationships — partners often feel helpless (cannot fix it), frustrated (by the limitations it imposes on family life), or guilty (for having moments of resentment). The patient feels guilty about the burden she represents. Both partners are suffering, neither knows how to talk about it. Family psychoeducation about chronic pain is underused and highly effective.

"How is your partner managing through this? It affects them too, often in ways neither of you are talking about. Part of the treatment I am recommending involves understanding that — there are resources for families and partners of people with chronic pain."
💰
Financial and Occupational Impact

Margaret is retired (somewhat younger than normal retirement age — suggests the pain contributed to early retirement). For patients still working, chronic pain causes significant occupational disruption. The Equality Act 2010: chronic pain that substantially limits daily activities is a disability — workplace adjustments are a legal entitlement. PIP, ESA, Access to Work are relevant for patients with significant disability.

"I want to make sure you are aware of the financial support you may be entitled to — DWP benefits, PIP. These are not "giving up" — they are practical support that might reduce some of the financial stress that amplifies the pain."
😤
Medical Invalidation and Distrust

"You've been told your scan is fine and you should be better" is one of the most harmful things healthcare can say to a chronic pain patient. The accumulated effect of this repeated invalidation is a patient who has lost trust in the healthcare system and arrives at every consultation expecting to be dismissed again. Rebuilding trust requires explicit acknowledgment of the invalidation, not just a new diagnosis.

"I want to be direct about something: the experience of being told your scan is normal and you should be fine — when you are clearly not fine — is a failure of how we have communicated about this condition. Your pain is real. The science of how we understand it has changed, and so should the treatment."
🏠
Social Isolation

Chronic pain progressively reduces social engagement — activities are cancelled, relationships maintained only by the most committed, and isolation deepens. Social isolation amplifies pain through two mechanisms: increased focus on pain (nothing else to think about) and increased activation of central sensitisation pathways (social exclusion activates the same neural pathways as physical pain). Social prescribing and peer support groups are underused but evidence-based interventions.

"You mentioned you have stopped going out as much. I want to be honest: the isolation is actually amplifying your pain — the brain processes social pain and physical pain through the same pathways. Getting back to social connections, even gradually, is part of the treatment."
🔮
Prognosis

Chronic primary pain is not reliably curable but is very manageable. Most patients who engage with the evidence-based pathway (exercise + ACT + medication optimisation) achieve significant improvement in function and quality of life, with pain reduced but often not eliminated. The framing of "living well with pain" rather than "waiting for the pain to stop before living" is the therapeutic core of ACT and the most important prognostic message.

"The goal is not a pain-free life — though some people do achieve that. The goal is a life that feels full and meaningful, with the pain present but not defining it. Most people who engage fully with this programme describe that as achieved within 6–12 months."
7H — Follow-up
1
4 Weeks — Exercise Progress + Opioid Taper + PHQ-9

Exercise: has the patient started? What activity? What frequency? Barriers to exercise identified and addressed. Tramadol taper: first 10% reduction tolerated? Withdrawal symptoms? Temporary pain increase expected. Duloxetine started? Tolerability. ACT referral confirmed? PHQ-9 trend. Any new red flag symptoms? Self-management resources accessed?

Exercise: one specific activity namedOpioid taper: 10% first step completed
2
8–12 Weeks — Response Assessment + ACT Progress

Function (not just pain: has the patient walked further? re-engaged with any activity?). Pain NRS vs baseline (function more important than pain intensity). ACT sessions started? Catastrophising reducing? PHQ-9. Opioid taper: next 10% step. Duloxetine at 60mg? Sleep improving? Any new concerns?

Function: primary outcome, not pain scoreACT engagement: catastrophising trend
3
3–6 Months — Major Review

Function significantly improved (return to meaningful activities)? Opioid substantially reduced or stopped? PHQ-9 in remission range? Exercise established as habit? ACT complete? Pain NRS. If inadequate response: pain clinic referral; MPMP consideration; review diagnosis. Red flags re-screened. Medication review: is duloxetine still needed?

Return to valued activities: ACT primary outcomeInadequate response → pain clinic / MPMP
4
Annual Review

Annual chronic pain review: PHQ-9; medication review (is each drug still working? is each drug still indicated?); opioid prescribing justification documented; functional status; any new red flags; falls risk if on amitriptyline, pregabalin, or opioids; cardiovascular and renal monitoring if on NSAIDs.

Annual medication review: document benefit assessmentOpioid justification documented annually
7I — Monitoring

Chronic pain annual review — NICE NG193 minimum standard

At every chronic pain medication review: function assessment (what can the patient do now vs 3/6/12 months ago?); PHQ-9 (comorbid depression; suicide risk); opioid justification (document that opioid is providing functional benefit — if it is not, begin taper discussion); eGFR (NSAID, gabapentinoid, tramadol dose review); falls risk (opioids; amitriptyline; gabapentinoids in elderly); exercise engagement (is the patient engaged with active management?); weight (opioids cause weight gain; sedentary lifestyle compounds this).

7J — Safety-netting

⚠ Safety-netting for chronic pain

🔴 New neurological symptoms — emergency
"I want you to know what to look out for — even though we have excluded any serious cause today, your pain pattern could change. If you ever develop numbness or tingling in the inner part of your thighs or around the back passage, or if you have any new difficulty controlling your bladder or bowel, or if both legs become weak — please call 999. These are symptoms that need immediate investigation. Do not wait for an appointment."
Cauda equina syndrome is the most serious emergency in back pain and can develop in patients with established chronic pain. Pre-warning specifically prevents delayed presentation and permanent neurological injury.
💊 Opioid taper — pain may temporarily worsen
"When we start reducing the tramadol, you will almost certainly have a period — 2–4 weeks — where the pain feels worse than usual. This is expected. It is the nervous system's sensitivity temporarily increasing as it adjusts to the lower opioid level. It will settle. Please contact us if it is severe — but please do not interpret this as a sign that we made the wrong decision."
The expected pain increase during opioid taper is the most common reason patients reverse the taper. Pre-warning with a specific timeframe ("2–4 weeks") and a specific explanation ("OIH reversal phase") significantly reduces early taper abandonment.
🟠 Suicidal ideation — direct pathway
"If the pain and the hopelessness about it ever reach a point where you feel you cannot go on — please contact us the same day, call the Samaritans on 116 123, or go to A&E. Chronic pain is one of the conditions most associated with suicidal feelings, and I want you to know that there is always a next step we can take in the treatment — we are not out of options."
Chronic pain doubles suicide risk. Pre-warning with specific crisis resources and an explicit message that "we are not out of options" addresses the hopelessness-driven suicidality that is the primary risk mechanism.
4 WeeksExercise started; opioid first 10% taper; PHQ-9; ACT waiting; duloxetine tolerability
12 WeeksFunction assessment; ACT progress; opioid taper; PHQ-9; pain NRS vs baseline
AnnualMedication review; opioid justification; function; PHQ-9; eGFR; falls risk
🎓 SCA Checkpoint — Step 7 (Final)TasksRelating to OthersGlobal Skills
Closing
"I am not going to prescribe morphine today — and I want to explain why, because I want to give you something that will actually work better. Morphine would produce the same effect as the tramadol: short-term help, then increasing tolerance, then more pain."
"What the evidence shows is that for pain like yours, exercise is more effective than any medication. I want to refer you for a supervised exercise programme and a specific psychological therapy for pain — called ACT — that is NICE-recommended."
"I also want to discuss a slow, gradual plan to reduce the tramadol over several months. Reducing it — not stopping it abruptly — is likely to improve your pain in the long run."
"I want to check your mood — from what you have told me, the pain has significantly affected your wellbeing and your activities. PHQ-9 score today was 12 — I want to start duloxetine, which treats both the depression and the pain."
"If anything new happens — numbness in the inner thigh, bladder problems, both legs going weak — please call 999 immediately. Is there anything else before we finish?"
Deductions
  • Prescribing morphine or escalating opioids — NICE NG193 explicit recommendation against this for chronic primary pain
  • Not validating the pain as real before explaining the biopsychosocial model
  • Not explaining OIH as the reason for declining opioid escalation
  • Not offering exercise and ACT as specific, evidence-based alternatives
  • Not completing PHQ-9
  • Not addressing the cauda equina safety-net
Tasks — full criteria
  • NICE NG193 framework applied; morphine not prescribed; OIH explained
  • Exercise and ACT/CBT offered specifically (not generic lifestyle advice)
  • Tramadol taper plan discussed (10% per 2–4 weeks)
  • PHQ-9; duloxetine for depression + pain
  • Cauda equina safety-net given verbally
Relating to Others
  • Pain validated as real before explaining biopsychosocial model
  • "Dismissed" experience acknowledged
  • Biopsychosocial model in plain language (smoke alarm analogy)
  • ICE all three; catastrophising identified
  • Opioid taper discussed non-judgmentally
  • Prognosis realistic and hopeful
🔴 Red
Morphine prescribed; pain invalidated; biopsychosocial model not used; PHQ-9 not done; exercise and ACT not mentioned; OIH not explained; cauda equina safety-net absent; gabapentinoid prescribed for chronic primary pain
🟠 Amber
Pain validated; morphine declined but OIH not explained; exercise mentioned but not referred; PHQ-9 done; tramadol taper not discussed; ACT not mentioned; catastrophising not explored
🟢 Green
Pain validated; biopsychosocial model explained; OIH explained; morphine declined with evidence; exercise + ACT offered; tramadol taper plan; PHQ-9; duloxetine; cauda equina safety-net; catastrophising assessed; ICE all three; closing question
Chronic Pain — SCA Consultation Scorecard
NICE NG193 (2021) · Exercise + ACT first-line · No opioid escalation · OIH explained · PHQ-9
0/ 33 pts
🌐
Global Skills
Structure, language, responsiveness
0/7
Tasks
Clinical reasoning, referral, management
0/15
🤝
Relating to Others
Communication, rapport, shared decision making
0/11
RAG Self-Assessment
🔴 Red
Morphine prescribed; pain invalidated; biopsychosocial model not used; PHQ-9 absent; exercise and ACT not mentioned; OIH not explained; gabapentinoid for primary pain; cauda equina not screened
🟠 Amber
Pain validated; morphine declined but OIH not explained; exercise mentioned but not referred; PHQ-9 done; tramadol taper not discussed; ACT not mentioned; catastrophising not explored; ICE partial
🟢 Green
Pain validated; biopsychosocial model; OIH; morphine declined with evidence; exercise + ACT offered and referred; tramadol taper; PHQ-9; duloxetine; cauda equina safety-net; catastrophising assessed; ICE all three; closing question
011172533
Fail
Borderline
Pass
Strong pass
📋
Complete the checklist to see your score
"I've been in chronic pain for 4 years and the tramadol isn't doing enough any more. I'd like to try something stronger — morphine, or something like that. The last two doctors I've seen have just told me my MRI is fine and I should be better. I'm not."
Who you are

Margaret Davies, 58, retired secondary school teacher (took early retirement 2 years ago, primarily due to the pain). Lives with husband David (62, retired). Two grown-up children. She was previously active — gardening, long country walks, book club. All stopped. She now spends most of her day at home, sitting with heat pads, watching television. She has lost her social circle because she keeps cancelling. Her husband is supportive but frustrated — "he tries to help but doesn't really understand why I'm not getting better." PHQ-9 = 12 (mild-moderate depression — she has not connected her low mood to the pain explicitly; she attributes it to "not being able to do anything"). She is a capable, intelligent, and articulate woman who has been failed by healthcare and arrives defensive and sceptical.

Hidden clinical concerns

Primary demand: Morphine or equivalent. She has read about it online. She believes stronger pain medication is the logical next step after tramadol has been inadequate. She will initially resist the biopsychosocial explanation — "I don't want to be told it's all in my head." She responds positively if the GP clearly distinguishes "in your head" (imagined) from "in your nervous system" (real, just a different mechanism).

Secondary agenda: She wants to be believed. The most therapeutic thing the GP can say is "your pain is real." She has been in pain every day for 4 years and no one has acknowledged that. Everything else is secondary to this.

Catastrophising pattern: "The pain is never going to get better. There must be something the MRI missed. Every time I move it feels like I am doing more damage." She has not been assessed for catastrophising — it will emerge if the GP asks about what goes through her mind when the pain is bad.

Clinical details if asked
  • Pain location: central low back, radiating to left buttock and posterior thigh (non-dermatomal — does not reach below knee); no saddle anaesthesia; no bladder/bowel problems; no bilateral leg symptoms
  • Pain character: aching, constant 6/10 at rest; 8–9/10 with activity; worse in morning; slightly better after gentle movement but fear prevents her from testing this
  • Current medications: tramadol 100mg BD; duloxetine 60mg OD (started 8 months ago — "helps a bit with mood but not much with pain"); paracetamol PRN (rarely takes — "it doesn't do anything")
  • Activities: stopped all walking 18 months ago; stopped gardening 2 years ago; drives short distances only; stopped book club 6 months ago
  • PHQ-9 = 12 (question 9: passive death wish "sometimes feel life isn't worth living" — 1 point; no active suicidal ideation)
  • Catastrophising: "I think every time I try to do something I am making it worse. I lie awake thinking about the pain."
Reactions to key moments
  • When pain is validated: Visible relief — "That is the first time a doctor has actually said that." Then willingness to listen.
  • On opioid escalation declining: "So you're saying the tramadol is making it worse? That seems mad." → Receptive to OIH explanation if specific and non-blaming.
  • On exercise recommendation: "I can't exercise — the pain stops me." → Receptive to graded exercise explanation if the mechanism is explained and a very small starting point is offered.
  • On ACT: "I don't want to be told to just accept the pain and move on." → Receptive if ACT is distinguished from dismissal: "It is not about giving up. It is about getting your life back alongside the pain."
  • Challenge line: "But if the exercise and the therapy were going to work, why haven't all the previous treatments worked? I've tried physio before and it made things worse."
"I've tried physiotherapy before and it made everything worse. Why is this going to be any different? And are you seriously telling me that reducing my pain medication is going to help? That seems completely backwards."

Resolution: Margaret will accept the plan if the GP: (1) validates her pain as real and explicitly distinguishes "not on the scan" from "in your head"; (2) explains OIH specifically — why tramadol is part of the problem, not just inadequate; (3) explains that the previous physio likely involved passive treatment (massage, manipulation) whereas this referral is for a specific graded exercise programme for central sensitisation; (4) acknowledges her fear of exercise making things worse, with the mechanism of how graded exercise works differently from traditional physio; (5) starts duloxetine optimisation (she is on 60mg — discuss whether this needs review; or add comment about the depression component); (6) completes PHQ-9 and addresses the low mood explicitly; (7) gives the cauda equina safety-net. She will disengage if morphine is prescribed, if her pain is minimised, or if the biopsychosocial explanation is given without first validating that the pain is real.

🏥
Clinic Quick Reference
Chronic Pain — Clinical Decision Framework
NICE NG193 (2021) · Exercise + ACT first-line · No opioid escalation for primary pain
expand
🚦 1 — Triage Algorithm
Chronic pain → re-screen red flags → PHQ-9 → classify primary vs secondary → NICE NG193 pathway or specific secondary treatment
🔴 Urgent
  • Cauda equina: saddle anaesthesia + bilateral leg weakness → 999
  • Night pain + weight loss >50y → urgent MRI; malignancy screen
  • Fever + back pain + focal neurology → spinal infection; admission
  • Suicidal ideation with plan: same-day crisis
Red flag exclusion mandatory at every chronic pain review
🟠 Specialist
  • Refractory after exercise + ACT + pharmacotherapy: pain clinic; MPMP
  • Confirmed neuropathic pain: duloxetine + gabapentinoid appropriate
  • Opioid tapering requiring specialist support
Pain clinic: MDT approach; not medication escalation
🟢 NICE NG193
  • Chronic primary pain: exercise (graded) + ACT/CBT + comorbid depression treatment
  • Opioid de-prescribing: 10% taper every 2–4 weeks
Validate → biopsychosocial model → exercise → ACT
💊 2 — NICE NG193 Pharmacology
DO Offer (when indicated)
Depression + pain: Duloxetine 30→60mg OD (SNRI; pain + depression)
Fibromyalgia / neuropathic: Amitriptyline 10mg nocte; duloxetine
Localised pain: Topical diclofenac (much safer than oral NSAID)
Neuropathic only: Gabapentinoid (not for primary pain)
⛔ Do NOT Start (Chronic Primary Pain — NICE NG193)
Opioids: worsen OIH; no long-term benefit; taper if already prescribed
Gabapentinoids: no evidence for primary pain; Class C CD; harms
Paracetamol: insufficient evidence of benefit; de-prescribe if no benefit
NSAIDs (long-term): insufficient evidence; significant CV/GI/renal risks
NICE NG193
2021: exercise + ACT first-line; do NOT start opioids/gabapentinoids/paracetamol for primary pain
Exercise
Most effective single intervention for chronic primary pain; any modality; supervised superior initially
OIH
Opioid-induced hyperalgesia: chronic opioids increase pain sensitivity; explains escalating tolerance
10%
Opioid taper rate: 10% dose reduction every 2–4 weeks; never abrupt; pain psychology alongside
60%
Depression comorbidity in chronic pain — PHQ-9 mandatory every consultation
Cauda equina
Re-screen at every back pain consultation: saddle anaesthesia + bilateral leg weakness → 999
ACT
Acceptance and Commitment Therapy: NICE first-line; values-based living with pain; reduces catastrophising
PNE
Pain Neurophysiology Education alongside exercise: superior to exercise alone; changes illness model
⚠ 3 — Safety-Netting
🔴 Cauda equina — emergency
"Saddle numbness, bilateral leg weakness, bladder/bowel problems → call 999; do not wait for appointment."
💊 Opioid taper — temporary pain increase
"Pain may temporarily worsen during opioid taper — expected 2–4 weeks; OIH reversal phase; will settle."
🟠 Suicidal ideation
"PHQ-9 item 9 and direct screen; chronic pain doubles suicide risk. Samaritans 116 123 if in crisis."
Follow-up timeline
4w
4 weeks: Exercise started; opioid taper step 1; PHQ-9; duloxetine
12w
12 weeks: Function (primary outcome); ACT progress; opioid taper
Annual
Annual: Medication review; opioid justification; eGFR; falls risk
📌 NEVER escalate opioids for chronic primary pain per NICE NG193
🚨 Red flags: Cauda equina (saddle numbness + bilateral leg weakness → 999) · Night pain + weight loss → malignancy · Fever + back pain + neurology → spinal infection · Suicidal ideation: PHQ-9 item 9; direct screen · Rapidly progressive neurological deficit: urgent MRI
🛡️ Safety rules: NICE NG193: never escalate opioids for chronic primary pain · Gabapentinoids not for chronic primary pain · Opioid taper: 10%/2–4 weeks; never abrupt · PHQ-9 mandatory every chronic pain consultation · Cauda equina safety-net every back pain consultation · Opioid justification documented annually · Gabapentinoid + opioid combination: respiratory depression risk
🎓
SCA Exam Quick Reference
Chronic Pain SCA — Validate · OIH · Exercise · ACT · No Opioid Escalation
Tasks · Relating to Others · Global Skills
expand
🕐 12-Minute Consultation Flow
0–1 min
Validate Pain as Real
"Before we go through everything, I want to say something: your pain is real. A normal MRI does not mean the pain is imagined — it means this type of pain works differently from what shows up on a scan."
Relating to OthersGlobal Skills
✗ Not validating before explaining · ✗ Reinforcing "MRI is fine, you should be better" · ✗ Dismissing the request before engaging
1–5 min
Biopsychosocial + Red Flags + PHQ-9
"Tell me about what a typical day looks like — not just where the pain is, but what the pain has done to your life."
Re-screen red flags (cauda equina). PHQ-9. Catastrophising screen. NICE NG193 framework in mind: function, not pain score, is the outcome. ICE: structural model; "dismissed" concern; morphine expectation.
TasksRelating to Others
✗ Not re-screening cauda equina · ✗ PHQ-9 not done · ✗ Missing catastrophising
5–7 min
Biopsychosocial Model + OIH
"Think of your pain system like a smoke alarm that has become oversensitive. It fires when there is no real danger. The MRI is normal because the problem is in the alarm system, not the structure it protects."
"Long-term opioids — like the tramadol — can actually increase the nervous system's sensitivity over time. That is called opioid-induced hyperalgesia. It is why the tramadol is working less well."
TasksGlobal Skills
✗ Not explaining why MRI normal doesn't mean imagined · ✗ Not explaining OIH · ✗ Biopsychosocial framing without validating first
7–10 min
Exercise + ACT + Opioid Taper
"The most effective treatment for chronic primary pain is exercise. NICE specifically recommends it above any medication. I am referring you for a supervised exercise programme and for pain-focused therapy called ACT."
Decline morphine: OIH mechanism already explained. Tramadol taper: 10%/2–4 weeks; pain psychology alongside; expected temporary pain increase warned. Duloxetine for depression + pain.
TasksRelating to Others
✗ Morphine prescribed · ✗ Gabapentinoid added · ✗ Exercise as afterthought, not first-line
10–12 min
Safety-Net + PHQ-9 + Close
"If you ever notice numbness between your thighs or problems with your bladder — call 999. Do not wait. Also: if the pain and the hopelessness about it ever lead to thoughts of harming yourself, please contact us that day or call Samaritans on 116 123."
4-week follow-up. "The goal is not to eliminate pain — it is to get you back to a life that feels meaningful." Closing question.
TasksGlobal Skills
✗ Cauda equina safety-net absent · ✗ Suicidal ideation not screened · ✗ No follow-up plan
🔴🟠🟢 RAG — All 3 Domains
Tasks
🟢
NICE NG193 applied; morphine declined with OIH explanation; exercise + ACT referred; tramadol taper; PHQ-9; duloxetine; cauda equina; suicidal ideation; biopsychosocial assessment complete; red flags; follow-up
🟠
Pain validated; morphine declined but OIH not explained; exercise mentioned; PHQ-9 done; tramadol taper not discussed; ACT not mentioned; cauda equina not screened
🔴
Morphine prescribed; pain invalidated; biopsychosocial model absent; PHQ-9 not done; gabapentinoid added for primary pain; cauda equina not screened; OIH not explained
Relating to Others
🟢
Pain validated first; "dismissed" experience acknowledged; biopsychosocial plain language; opioid taper non-judgmental; exercise with mechanism; catastrophising compassionate; ICE all three; shared decision-making; closing question
🟠
Pain validated; ICE partial; OIH not explained to patient; exercise without mechanism; catastrophising not explored; taper not discussed with patient
🔴
Pain minimised; "your MRI is fine" repeated; no ICE; exercise as dismissal; morphine given; no shared decision-making
Global Skills
🟢
Validation first; open question (function not pain score); biopsychosocial model plain language; OIH accessible; exercise mechanism; 12 minutes structured; chunk-and-check
🟠
Validation given; biopsychosocial model explained but jargon-heavy; clinical agenda driven; ran over without completing plan
🔴
Pharmaceutical frame only; no biopsychosocial; pain minimised; no plain language
💬 Key Phrases
💭 Validate first
"Your pain is real. A normal MRI doesn't mean imagined — it means this type of pain lives in the nervous system's sensitivity, not the tissue. Both are equally real. They just need different treatment."
😟 OIH explanation
"Long-term opioids can make the nervous system more sensitive over time — it is called opioid-induced hyperalgesia. That is why the tramadol is working less well. Morphine would produce the same effect: short-term relief, then more sensitivity."
🎯 Exercise as most effective
"Exercise is the most evidence-based treatment for chronic primary pain — more effective than any medication. The mechanism is direct: it reduces the nervous system's sensitivity through pathways that no tablet can replicate."
🔬 ACT distinction
"ACT is not about accepting that you will always be in pain and just getting on with it. It is about getting your life back alongside the pain — returning to the things that matter to you, rather than waiting for the pain to disappear before you start living."
📋 Opioid taper
"I want to suggest a very gradual reduction of the tramadol — 10% at a time, over many months. When we reduce it slowly, the nervous system adjusts and in most cases people end up with better pain control. I will support you throughout."
💚 Treatment goal
"The goal is not to be pain-free — though some people do achieve that. The goal is a life that feels full and meaningful, with the pain present but not defining it. That is achievable."
🚫 8 Danger Zones
Opioid escalation for chronic primary pain→ NICE NG193 (2021) explicitly recommends against starting or escalating opioids for chronic primary pain. OIH means escalation makes long-term outcomes worse. This is the highest-yield NICE NG193 point in SCA.
Pain invalidated (MRI normal = should be fine)→ The most harmful clinical response to chronic primary pain. Pain is real. Normal MRI means nociplastic/central sensitisation mechanism, not imagined pain. Invalidation destroys the therapeutic relationship and prevents effective treatment engagement.
Gabapentinoid prescribed for chronic primary pain→ NICE NG193: do NOT start gabapentinoids for chronic primary pain. They have evidence only for confirmed neuropathic pain. For non-neuropathic chronic primary pain, prescribing gabapentinoids is against current guidance and exposes the patient to significant harm.
Exercise offered as afterthought, not first-line→ NICE NG193 positions exercise as the primary intervention for chronic primary pain — not a lifestyle suggestion added at the end. It must be presented as "the most effective treatment" with a mechanism explanation and a specific supervised referral.
ACT/CBT not offered→ NICE NG193: ACT and pain-focused CBT are first-line alongside exercise. They are not "soft" options — they have a stronger evidence base for chronic primary pain than any analgesic. Not mentioning them is an incomplete management plan.
PHQ-9 not completed→ Depression in 40–60% of chronic pain patients. Depression amplifies pain; treating depression significantly improves pain outcomes. PHQ-9 is mandatory at every chronic pain consultation. Suicidal ideation (item 9) in a doubled-risk population must not be missed.
Cauda equina not re-screened→ Cauda equina can develop in patients with established back pain. Every consultation involving back pain must include a brief cauda equina screen (saddle anaesthesia; bilateral leg weakness; bladder/bowel). The safety-net must be given verbally.
OIH not explained when declining opioid escalation→ Declining morphine without explaining OIH leaves the patient feeling dismissed. The explanation — "opioids make the nervous system more sensitive over time; that is why the tramadol is working less well" — transforms the refusal into a therapeutic insight and opens the door to the taper discussion.
💊 Drug Quick-Pick by Scenario
Depression + chronic pain
Duloxetine 30→60mg OD
SNRI; addresses both pain and depression; licensed fibromyalgia/DPNP
Fibromyalgia / sleep + pain
Amitriptyline 10mg nocte
RCT evidence fibromyalgia sleep+pain; neuropathic; anticholinergic in elderly
Localised pain only
Topical diclofenac gel
Much safer than oral NSAID; negligible systemic absorption; OTC available
Confirmed neuropathic pain
Duloxetine OR pregabalin
ONLY for neuropathic (NOT primary pain) — NICE NG193 prohibition for gabapentinoids in primary pain
Opioid already prescribed
TAPER 10%/2–4 weeks
OIH explanation; pain psychology alongside; never abrupt; buprenorphine as bridge if dependent
⛔ Chronic Primary Pain — NEVER
Opioids / Gabapentinoids
NICE NG193 explicit prohibition for chronic primary pain
⛔ NEVER escalate opioids for chronic primary pain (NICE NG193) · NEVER start gabapentinoids for chronic primary pain (only neuropathic) · Exercise + ACT are more effective than any pharmacotherapy for chronic primary pain · Duloxetine: appropriate when depression OR neuropathic pain comorbid · Opioid taper: 10%/2–4 weeks; pain psychology alongside; explain OIH to patient · Cauda equina safety-net every back pain consultation · PHQ-9 mandatory every chronic pain consultation
Reviewed: July 2026 · citations verified against current NICE / UK guidance